-- Imbruvica is popular therapeutic drug used to treat patients suffering from chronic lymphocytic leukemia along with Waldenstrom macroglobobulinemia which is perceived as a type of non-Hodgkin lymphoma and small lymphocytic lymphoma. The application process of imbruvica is either as an individual drug treatment or it is coupled with other drugs. Imbruvica is studied under numerous research initiatives understanding its potential role in treatment of other types of cancer. Furthermore, the drug is independently used in treating adults with mantle cell lymphoma. The physiological function of imbruvica targets specific course of action blocking a protein called Bruton’s tyrosine kinase enabling prevention of any further growth of cancer cells.
The major driving factor escalating the growth of the imbruvica market is the increasing incidence of cancer among varied set of population coupled with an advancing healthcare sector witnessing the emergence of novel therapeutic procedures and targeted therapies for patients with lymphoma and leukemia are successfully boosting the probable opportunities for development of imbruvica-enabled therapy. Targeted therapies are gaining immense popularity owing to the higher specificity attributed by the drugs. For instance, a drug is utilised that is capable of interfering with particular molecular targets responsible for the growth, progression and metastasis of cancer.
The global Imbruvica market was valued at USD 6.20 billion in 2018. Emergence of novel cancer therapies and targeted therapy for rising number of patients with lymphomas and leukemia are the prime factors for the growth of the global Imbruvica market.
Get a Latest Updated Sample Copy of the Report @ https://www.adroitmarketresearch.com/contacts/request-sample/839
Chronic Lymphocytic leukemia is the most dominant application segment being the most common type of blood cancer with maximum prevalence in people aged above 70. Regionally, the Imbruvica market is most dominant in U.S which is observed to be a major hub for novel target therapies. The region expresses the prevalence of key players invested in development of highly advanced cancer treatment. Other than this, North America houses a large patient pool with a large number of populations suffering from different cancer types affected by lifestyle and other factors which is boosting a massive growth of the global imbruvica market. Furthermore, the imbruvica market in the U.S holds added advantage of increasing private initiative and government support encouraging research activities in enhanced therapeutic procedures. The impact of lifestyle such as higher obesity rates, smoking, exposure to certain chemicals and radiation are considered to the major causative factors of blood cancer in the U.S.
Along with this, growing healthcare expenditure in emerging countries such as China and India are increasing the growth of R&D outlines and activities with ideal government support encouraging the growth of the imbruvica market. Increasing vulnerability towards different cancer types and availability of medical benefits are some major factors significantly encouraging molecular studies and targeted therapy research activities. Major global authorities and global regulation bodies such as the Food and Drug Administration are globally driving the growth of targeted drugs which is propelling the growth of the global imbruvica market with increasing healthcare infrastructure and financial aid offered by some of the major market leaders.
Janssen Pharmaceuticals and Pharmacyclics LLC are prominent Imbruvica market players in the U.S., however only Janssen Pharmaceuticals markets Imbruvica worldwide.
If you have any questions on this report, please reach out to us @ https://www.adroitmarketresearch.com/contacts/enquiry-before-buying/839
Key Segments of the Global Imbruvica Market
Application Overview, 2015-2025 (USD Million)
• Mantle Cell Lymphoma
• Chronic Lymphocytic Leukaemia
• Waldenström's Macroglobulinemia
• Relapsed/Refractory Marginal Zone Lymphoma
• Chronic Graft-Versus-Host-Disease
Regional Overview, 2015-2025 (USD Million)
• U.S
• Europe
• India
• Japan
• China
• Southeast Asia
• Central & South America
Some Major Points from Table of Contents:
List of Tables
TABLE 1 Global Imbruvica Market Size by Regions (2018-2025)
TABLE 2 Imbruvica Market Share by Regions (2018-2025)
TABLE 3 Development History and FDA Approval Process for Imbruvica in the U.S.
TABLE 4 U.S. Imbruvica market revenue, by application, 2018 – 2025 (USD million)
TABLE 5 Europe market revenue, by application, 2019 – 2025 (USD million)
TABLE 6 List of 17 Drugs to be Covered by China's National Insurance
TABLE 7 China market revenue, by application, 2018 – 2025 (USD million)
TABLE 8 Treatment Regimens and Drug Acquisition Costs
TABLE 9 Japan market revenue, by application, 2018 – 2025 (USD million)
TABLE 10 South East Asia market revenue, by application, 2018 – 2025 (USD million)
TABLE 11 India Imbruvica market revenue, by application, 2018 – 2025 (USD million)
TABLE 12 Central & South America market revenue, by application, 2018 - 2025 (USD
million)
TABLE 13 Market Size Forecast by Application (2019-2025)
Browse the complete report Along with TOC @ https://www.adroitmarketresearch.com/industry-reports/imbruvica-market
About Us :
Adroit Market Research is an India-based business analytics and consulting company incorporated in 2018. Our target audience is a wide range of corporations, manufacturing companies, product/technology development institutions and industry associations that require understanding of a Market’s size, key trends, participants and future outlook of an industry. We intend to become our clients’ knowledge partner and provide them with valuable Market insights to help create opportunities that increase their revenues. We follow a code- Explore, Learn and Transform. At our core, we are curious people who love to identify and understand industry patterns, create an insightful study around our findings and churn out money-making roadmaps.
Contact Info:
Name: Ryan Johnson
Email: Send Email
Organization: Adroit Market Research
Address: 3131 McKinney Ave Ste 600, Dallas, TX75204, U.S.A.
Phone: +1.210.667.2421
Website: https://www.adroitmarketresearch.com/industry-reports/imbruvica-market
Release ID: 89015673
Google
RSS